Advertisement

Topics

Classen Immunotherapies, Inc. Company Profile

13:16 EDT 18th September 2018 | BioPortfolio

Tel: 410-377-8526


News Articles [184 Associated News Articles listed on BioPortfolio]

Infographic: Discovering The Current Landscape of Immunotherapies

Together with the experts at Theravectys, we have created an absolutely amazing Infographic full of cool and fun facts about Immunotherapies. Click on the image below to download the complete Infogra...

Cancer immunotherapies drugs market set for substantial growth, says GBI Research

Increased uptake of immune checkpoint inhibitors drives growth The global market for cancer immunotherapies currently tops $33 billion in value,...Read More... The post Cancer immunotherapies drugs ma...

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies

Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of ...

Turning up the heat on resistant tumours with novel immunotherapies

A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don't respond to the newer cancer immunotherapies. Robe...

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH (Reuters) - The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they...

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

Immunotherapies in Oncology and Their Side Effect Profiles

Learn about the side effect profiles of the various classes of new and emerging immunotherapies used for cancer treatment. Journal of the American Board of Family Medicine

Affimed ties with Roche in cancer immunotherapies deal

Shares in Affimed more than doubled on news that it has signed a deal with Roche group Genentech to develop immunotherapies for various cancers.

Drugs and Medications [0 Results]

None

PubMed Articles [69 Associated PubMed Articles listed on BioPortfolio]

Toxicities with targeted therapies after immunotherapy in metastatic melanoma.

Over the last decade, melanoma treatment has taken rapid strides with the advent of immunotherapies and targeted agents. With these new agents, there has been a significant improvement in patient surv...

Animal Models for Studying Tumor Microenvironment (TME) and Resistance to Lymphocytic Infiltration.

In cancer immunotherapy, cytotoxic T or NK cells need to engage cancer cells to initiate the killing. However, in clinical studies and in mouse models, some solid tumors are found with no lymphocytes....

The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study.

The neutrophil-to-lymphocyte (ANC/ALC) ratio is associated with worse prognosis in patients with NSCLC on immunotherapies, but the role of ALC remains unclear. The previous radiation therapy causes ly...

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mecha...

Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients. Many therapies are currently ...

Clinical Trials [30 Associated Clinical Trials listed on BioPortfolio]

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other ...

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Recent scientific advances have shown the important role of immune system against cancer. Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment and gen...

GI-4000 With Adoptive Transfer in Pancreatic Cancer

The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be complete...

Prospective Tissue Collection Research Protocol

This study aims to collect matched donor tissue and blood to enable the development of a manufacturing process for potential immunotherapies.

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

The co-primary objectives will be to assess the safety and quality of life under treatment.

Companies [50 Associated Companies listed on BioPortfolio]

Classen Immunotherapies, Inc.

Tel: 410-377-8526

CTL ImmunoTherapies

CTL ImmunoTherapies, located in Chatsworth, California, is a biotechnology company focusing on the discovery, development and manufacturing of theraputic vaccines.

Advaxis, Inc. and Rodman & Renshaw, LLC

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform tech...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focus...

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fu...

More Information about "Classen Immunotherapies, Inc." on BioPortfolio

We have published hundreds of Classen Immunotherapies, Inc. news stories on BioPortfolio along with dozens of Classen Immunotherapies, Inc. Clinical Trials and PubMed Articles about Classen Immunotherapies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Classen Immunotherapies, Inc. Companies in our database. You can also find out about relevant Classen Immunotherapies, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record